Frederik Marmé

30PUBLICATIONS
214CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Cancer geneticsPredictive and prognostic markersOncology and carcinogenesis not elsewhere classifiedAboriginal and Torres Strait Islander medicine and treatments
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (30)

|Oct 30, 2026
5-year outcomes of chemotherapy de-escalation in HER2-positive early breast cancer and exploratory circulating tumor DNA analyses from the randomized phase 2 PHERGain trial.

|Jun 12, 2026
Constitutional BRCA1 Promoter Methylation in Patients With Ovarian Cancer: Results of the Observational AGO-TR1 Study.

|Mar 03, 2026
Harnessing lipid-driven immunometabolic pathways in omental metastases to enhance immunotherapy in patients with ovarian cancer.

Meggy Suarez-Carmona, Mareike Hampel, Xin-Wen Zhang

|Dec 03, 2025
Atezolizumab With Bevacizumab and Nonplatinum Chemotherapy for Recurrent Ovarian Cancer: Final Results From the Placebo-Controlled AGO-OVAR 2.29/ENGOT-ov34 Phase III Trial.

Philipp Harter, Frederik Marmé, Andrés Redondo

|Oct 01, 2025
Long non-coding RNAs as a biomarker for homologous recombination deficiency and parp inhibitor sensitivity in high-grade serous ovarian cancers.

Kai Doberstein, Johannes Panther, Eric Hahnen

|Jul 23, 2025
Primary Analysis of EPIK-O/ENGOT-ov61: Alpelisib Plus Olaparib Versus Chemotherapy in Platinum-Resistant or Platinum-Refractory High-Grade Serous Ovarian Cancer Without BRCA Mutation.

Panagiotis A Konstantinopoulos, Jae Weon Kim, Gilles Freyer

Pageof 5

Frequent Collaborators

10 joint publications

Carsten Denkert

9 joint publications

Peter Fasching

9 joint publications

Sibylle Loibl

8 joint publications

Valentina Nekljudova